Margaret Weaver

TL;DR: The results have proved the concept that a nucleoside inhibitor could be developed for potential treatment of flavivirus infections and suppressed peak viremia, reduced cytokine elevation, and completely prevented the infected mice from death.

TL;DR: The authors found that the molecular target of the indolcarboxamides was MmpL3, a protein that is essential for mycobacterial cell wall biosynthesis and growth, and were efficacious in treating Mtb infections in mouse models of acute and chronic TB with a favorable safety margin.

TL;DR: The pharmacokinetics and metabolism of nateglinide were studied in six healthy male subjects receiving a single oral (120 mg) and intravenous (60 mg) dose of [14C]nateglinides in randomized order.

TL;DR: The kinetics of distribution of lumiracoxib in synovial fluid are likely to extend the therapeutic action of the drug beyond that expected from plasma pharmacokinetics, and these data support the use of Lumiracxib in a once-daily regimen for the treatment of rheumatoid arthritis.

TL;DR: The results demonstrate that a prodrug approach using a nucleoside analog could potentially be developed for flavivirus antiviral therapy and inhibit DENV replication both in cell culture and in a DENV mouse model.